Scientist, Antibody Discovery
- Employer
- Molecular Templates, Inc.
- Location
- New York, NY, USA
- Start date
- Apr 1, 2021
View more
- Discipline
- Science/R&D, Biotechnology
- Required Education
- Other
- Position Type
- Full time
Job Details
Molecular Templates is a clinical-stage biopharmaceutical company focused on the discovery and development of differentiated, targeted, biologic therapeutics.
Our proprietary biologic drug platform technology, known as engineered toxin bodies, or ETBs, leverages the resident biology of a genetically engineered form of Shiga-like Toxin A subunit to create novel therapies with potent and differentiated mechanisms of action for cancer and other serious diseases. MTEM currently has multiple clinical-stage ETB candidates in development including MT-5111, TAK-169, and MT-6402. Additional preclinical compounds derived from our ETB platform technology are being advanced toward clinical development.
Additional information about Molecular Templates can be obtained at www.mtem.com.
Position Overview:
MTEM is seeking a highly motivated individual to help build an antibody discovery group. This hands-on position involves generation and screening of antibodies to be used in the company's ETB scaffold for the development of novel therapeutics. The Scientist will join a team of scientists to support therapeutic antibody discovery programs which focus on cancer. This position requires experience with phage display library construction and panning, antibody screening, expression, and optimization. This role will be located onsite in our Manhattan, NY office (Financial District).
Job Responsibilities:
- Designs and executes phage display library selections for lead identification of antibodies against challenging targets
- Builds and validates immune phage display libraries
- Performs high throughput screening of phage panning output
- Analyzes antibody sequence data (Sanger and/or NGS)
- Keeps a detailed and well-organized laboratory notebook
- Presents data at group meetings
- Stays current with literature and emerging trends in the discipline
- Performs other related duties as assigned
Qualifications:
- PhD in Immunology, Microbiology, Biochemistry or related field
- 2+ years of experience in an antibody discovery environment or
- Master's Degree and a minimum of 4 years of experience in antibody generation in an academic laboratory, or in the pharmaceutical and/or biotechnology industry
- Demonstrated successful track record with phage display library construction and panning
- Hands-on experience with whole cell panning techniques
- Working knowledge of high-throughput phage panning processes (e.g. semi-automated panning on the Kingfisher system and/or colony picking and sample processing on a QPix system)
- Proficiency in molecular biology techniques (PCR, cloning, primer design, plasmid preparation, etc.)
- Use of DNA sequence analysis/editing using tools such as Geneious or DNAStar
- Handling and manipulation of bacterial cultures
- Enzyme-linked immunosorbent assay (ELISA) development
- Experience with affinity maturation via phage display strongly desired
- Experience with B cell cloning a plus
- Ability to work on multiple projects in parallel to deliver results in rapid timeframes
- Ability to work independently in a dynamic environment
- Critical thinking, prioritization of tasks, attention to detail and troubleshooting
- Creativity in approaches to complex problems and desire to expand technical skillset
- Timely delivery of team goals and ability to build productive relationships with colleagues across MTEM's R&D department
Reporting Structure:
This position currently has no supervisory responsibilities. This position reports to the Director, Antibody Discovery.
Molecular Templates, Inc. is an Equal Opportunity Employer and offers competitive salaries and benefits.
Molecular Templates Inc https://mtem.isolvedhire.com
Company
Molecular Templates, Inc. (MTEM) is a clinical stage biopharmaceutical company focused on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases. The company primarily develops a pipeline of therapies through its proprietary biologic engineered toxin body (ETB) drug platform with unique mechanisms of actions which are highly differentiated from antibody drug conjugates (ADCs). MTEM is developing MT-6402, which is in a Phase I clinical trial for PD-1/PD-L1 antibody relapsed/refractory patients; MT-5111, which is in a Phase I clinical trial for the treatment of HER2-positive cancers; and MT-0169, which is in a Phase I clinical trial to treat relapsed/refractory myeloma. Additional preclinical compounds derived from our ETB platform technology are being advanced toward clinical development. Additional information about MTEM can be obtained at www.mtem.com.
OWNERSHIP: Public
STOCK SYMBOL: MTEM
STOCK EXCHANGE: NASDAQ
- Website
- http://mtem.com/
- Phone
- 512-869-1555
- Location
-
9301 Amberglen Blvd, Ste 100
Austin
TX
78729
US
Get job alerts
Create a job alert and receive personalized job recommendations straight to your inbox.
Create alert